1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Vivesto AB

Vivesto AB

OASMY
Vivesto ABUS flagOther OTC
0.00
USD
- -
- -
20,606.00Market Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
0.04
0.11
- -
0.03
0.02
1.32
0.15
0.01
- -
- -
- -
- -
Basic EPS, GAAP
-1.71
-2.07
-2.09
-2.39
-2.31
-1.22
-1.79
-0.07
-0.77
-1.89
-0.62
-0.19
-0.17
-0.16
Free Cash Flow per Basic Share
-3.15
-2.41
-2.29
-2.5
-2.04
-1.5
-1.16
-0.13
-1.05
-0.46
-0.34
-0.23
-0.26
-0.18
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-5.99
-7.07
-8.46
-10.41
-11.19
-9.18
-9.74
-7.1
-7.9
-9.15
-8.91
-9.1
-9.27
-9.03
Tangible Book Value per Share
-0.9
-2.12
-0.52
-1.62
-2.21
-1.31
-0.53
2.47
0.64
0.71
0.28
0.11
-0.09
0.11
Basic Weighted Avg Shares
42
51
56
59
69
97
112
153
172
189
206
206
206
206
Sales/Revenue/Turnover
- -
- -
2
6
- -
3
2
202
26
1
- -
- -
- -
- -
Operating Margin (%)
- -
-170,568.33
-5,234.98
-2,082.11
-81,792.44
-3,278.04
-7,613.59
-15.07
-502.14
-35,243.55
- -
- -
- -
- -
Depreciation Expense
5
5
5
5
5
5
31
20
29
252
57
3
2
1
Net Income, GAAP
-72
-105
-117
-142
-160
-118
-201
-11
-133
-357
-129
-40
-34
-33
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-175,186.67
-5,676.18
-2,220.92
-93,164.53
-3,723.79
-10,166.92
-5.22
-506.73
-35,134.19
- -
- -
- -
- -
Working Capital
-63
-131
-52
-117
-171
-143
-44
355
97
129
57
23
-19
23
LT Debt
- -
- -
- -
- -
- -
- -
- -
9
5
5
- -
- -
- -
- -
Total Equity
319
282
376
326
300
345
383
819
550
326
198
158
125
167
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
13
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
6
6
11
Market Capitalization
39
10
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
6
5
35
Cash, Cash Equivalents & STI
1
2
31
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
16
24
11
Payables & Accruals
- -
- -
- -
ST Debt
- -
13
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-3.56%
-30.84%
-21.32%
Free Cash Flow
64.01%
144.32%
13.58%
Net Income, GAAP
116.46%
236.29%
-14.27%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.04
-0.05
-0.05
-0.05
-0.19
2025
-0.04
-0.05
-0.03
-0.04
-0.17
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Erik Kinnman
Full Time Employees
4
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Address
Gustav III:s Boulevard 46 Solna MD Sweden 169 73
IPO Date
Oct 23, 2015
CIK
0001607245
Website
vivesto.com
Similar Companies
Eli Lilly and Company (LLY.TO)
Redcare Pharmacy N.V. (SAEYY)
Accent Microcell Limited (ACCENTMIC.NS)
MatsukiyoCocokara & Co. (MSMKF)
Kerala Ayurveda Limited (KERALAYUR.BO)
Shukra Pharmaceuticals Limited (SHUKRAPHAR.BO)
Business
Vivesto AB (STO: VIVE), a Swedish specialty pharmaceutical company headquartered in Solna, develops, manufactures and commercializes novel drug formulations utilizing its proprietary XR-17 nanotechnology platform to enhance solubility, efficacy and safety profiles of oncology therapeutics for human and veterinary applications; core products include Apealea (paclitaxel micellar), approved in the European Union and select territories for platinum-sensitive relapsed ovarian cancer in combination with carboplatin and commercialized through partnerships including Elevar Therapeutics in the US; Cantrixil, advancing in preclinical development targeting blood cancers such as acute myeloid leukemia; docetaxel micellar in phase 1b for prostate cancer; and veterinary offerings comprising Paccal Vet (paclitaxel micellar) in pilot clinical trials for canine splenic hemangiosarcoma and feline solid tumors, plus Doxophos Vet (doxorubicin micellar) for lymphoma and mammary carcinoma. Originally founded as Oasmia Pharmaceutical AB in 1999 and rebranded to Vivesto in March 2022, the company operates primarily from Sweden with global partnerships extending market access across Europe, North America, Asia and the CIS region, serving oncologists, veterinarians and patients with hard-to-treat cancers. Recent developments encompass a fully secured rights issue of SEK 53.8 million resolved in November 2025 to fund completion of Paccal Vet pilot studies, Cantrixil preclinical trials and partial repayment of Arwidsro credit facilities from April and November 2025; positive interim data advancements in both Paccal Vet and Cantrixil programs during autumn 2025; and sustained focus on securing commercial partnerships for pivotal studies targeted in 2026-2027.

Company News

APIChatGPT

  • defenseworld.net

    Financial Survey: Oasmia Pharmaceutical (OTCMKTS:OASMY) versus Acrivon Therapeutics (NASDAQ:ACRV)

  • seekingalpha.com

    Vivesto AB (OASMY) Discusses Pipeline Advancements in Paccal Vet and Cantrixil and Strategic Capital Raise Transcript